7 stories mentioning SHE:300723Updated just now
Every FINWIRES story that references SHE:300723, newest first.
ApicHope Pharmaceutical (SHE:300723) subsidiary obtained drug registration from China's medical products regulator for sertraline hydrochloride oral solution.The drug is used to treat depression and obsessive-compulsive disorder, according to a Thursday aftermarket filing with the Shenzhen bourse.Shares of the pharmaceutical company were down 3% Friday.
ApicHope Pharmaceutical (SHE:300723) said its gout drug, AR882, achieved the primary endpoint in a third phase trial for hyperuricemia patients.The 75-milligram group showed an 86.0% response rate, significantly outperforming febuxostat, according to a Friday filing with the Shenzhen bourse.AR882 demonstrated a favorable safety profile, with no permanent discontinuations or deaths due to adverse events.Shares of the pharmaceutical company were down 3% Friday.
ApicHope Pharmaceutical (SHE:300723) received clinical trial approval from China's National Medical Products Administration for its self-developed APH04935 tablets for weight control.The tablets are a selective small-molecule GLP-1R agonist that promotes insulin secretion and inhibits glucagon through the pancreas, and suppresses appetite, according to a Tuesday filing with the Shenzhen bourse.
ApicHope Pharmaceutical (SHE:300723) subsidiary Guangzhou ApicHope will sign a clinical research commissioning contract with Boji Medical Technology (SHE:300404) for 6.5 million yuan, according to a Saturday disclosure to the Shenzhen Stock Exchange.Boji will perform clinical research for the APH04935 tablets for weight management and obesity.Shares rose 4% during afternoon trading on Monday.
ApicHope Pharmaceutical (SHE:300723) received a drug registration certificate from China's National Medical Products Administration for its benzbromarone, according to a Friday filing with the Shenzhen bourse.The drug is indicated for gout, helping lower blood uric acid levels by inhibiting the reabsorption of uric acid by the kidney tubules, the company said in its filing.Sales of benzbromarone across China reached 269.5 million yuan in 2025, ApicHope said.
China's drug regulator approved ApicHope Pharmaceutical (SHE:300723) subsidiary Guangzhou ApicHope's clinical trial for its APH03571 tablets, according to a Thursday filing with the Shanghai bourse.The trial will test the effects of the drug on adult patients with relapsed or refractory acute myeloid leukemia.
ApicHope Pharmaceutical (SHE:300723) unit Guangzhou Yipinhong Pharmaceutical obtained drug registration from China's medical products regulator for aminocaproic acid injection.The drug is used to treat various bleeding caused by hyperfibrinolysis, according to a Friday fling with the Shenzhen bourse.The approval is valid until May 2031.Shares of the pharmaceutical company were up 3% Friday.
